期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

肿瘤血管生成及抗血管生成的临床应用 被引量：3

Tumor Angiogenesis and Clinical Applications of AntiangiogenesisPAN Hao(Shanghai Insti
下载PDF
导出
摘要 介绍了肿瘤血管生成的过程、特点、调控因素及其与肿瘤转移的关系,简要综述了抗血管生成的临床应用。 The process, characteristics and controlling factors of tumor angiogenesis and its correlation between cancerometastasis are introduced. The clinical application of antiangiogenesis is briefly reviewed.
作者 潘昊
机构地区 上海医药工业研究院
出处 《中国医药工业杂志》 CAS CSCD 北大核心 2006年第2期133-136,共4页 Chinese Journal of Pharmaceuticals
关键词 肿瘤 血管生成 抗血管生成 综述 tumor angiogenesis antiangiogenesis review
分类号 R978.5 [医药卫生—药品]
  • 相关文献

参考文献22

  • 1Folkman J. Clinical applications of research on angiogenesis[J] .N Engl J Med, 1995, 333 (26) : 1757-1763.
  • 2Folkman J. Tumor angiogenesis: therapeutic implications[J]. N Engl J Med, 1971, 285(21): 1182-1186.
  • 3Folkman J. Antiangiogenic gene therapy [J]. Proc Natl Acad Sci USA, 1998, 95(16): 9064-9066.
  • 4Gnarra JR, Zhou S, Merrill MJ, et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene [J]. Proc Natl Acad Sci USA, 1996, 93 (20) : 10589-10594.
  • 5Folkman J, Shing Y. Angiogenesis [J]. Biol Chem, 1992, 267(5) : 10931-10934.
  • 6Kawaguchi T, Yamamoto S, Kudoh S, et al. Tumor angiogenesis as a major prognostic factor in stage I lung adenocarcinoma[J]. Anticancer Res, 1997, 17 (5B) : 3743-3746.
  • 7Lala PK, Orucevic A. Role of nitric oxide in tumor progression:lessons from experimental tumors [J]. Cancer Metastasis Rev,1998, 17(1):91-106.
  • 8Dhanabal M, Ramchandran R, Waterman M J, et al. Endostatin induces endothelial cell apoptosis [J]. J Biol Chem, 1999, 274(17): 11721-11726.
  • 9Maeshima Y, Sudhaker A, Lively J C, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis [J].Science, 2002, 295 (5552): 140-143.
  • 10郑幼伟,郑启昌.肿瘤血管生成抑制物的研究进展[J].肿瘤研究与临床,2003,15(5):356-359. 被引量：4

二级参考文献63

  • 1柯祺,罗来骏.肝细胞癌CT表现与癌细胞核DNA含量,病理分级的关系[J].中华放射学杂志,1993,27(8):510-512. 被引量：6
  • 2沈冰奇,郑可国,许达生,薛玲,赖英荣.肝细胞癌边缘部的CT与病理对照研究[J].中华放射学杂志,1996,30(12):815-819. 被引量：17
  • 3Lin SW, Lee MT, Ke FC, et al. TGFbetal stimulates the secretion of matrix metalloproteinase 2(MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103 [J]. Clin Exp Metastasis, 2000, 18 (6) :493.
  • 4James K, Ralph W. Fibroblast growth factor 2:its structure and property, paracrine function, tumor angiogenesis, and prostate-related mitogenie and oncogenic fuctions[J]. Urology, 2000, 199(55) :800.
  • 5Heinrich MC,Blanke CD,Druker BJ ,et al. Inhibition of KIT ty -rosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies[J]. J Clin Oncol,2002,20(6) :1692.
  • 6Rosen LS, Kabbinavar F, Rosen P,et al. Phase I trial of SU-5416,a novel angiogenesis inhibitor, in patients with advanced malignancies[M]. 10th NCI-EORTC Symposium on new drugsin cancer therapy, 1998:16.
  • 7Cheresh PC, Montgomery AMP,Rosenfeld M,et al. Integrin α V　β3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels[J]. Cell, 1994,79(8) : 1157.
  • 8Paley PJ. Angiogenesis in ovarian cancer: molecular pathology and therapeutic strategies[J]. Curr Oncol Rep,2002,4(2) : 165.
  • 9Bernhard V,Olivier M, Wei-Jian Zhang, et al. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases[J]. Proc Natl Acad Sci,2000,97(9):4802.
  • 10Renhai Cao, Hua-Lin Wu, Veitonm? ki N, et al. Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis[J]. Proc Natl Acad Sci, 1999,96(10): 5728.

共引文献14

同被引文献34

  • 1王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量：625
  • 2郁皓,许泓瑜,华东.硫酸酯化灰树花多糖体外诱导胃癌细胞SGC-7901凋亡的研究[J].山东医药,2006,46(21):54-55. 被引量：4
  • 3栗衍华,谭成玉,王秀武,白雪芳,杜昱光.硫酸化多糖的制备及其生物活性的研究进展[J].精细与专用化学品,2006,14(16):6-9. 被引量：17
  • 4Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008 [ J]. CA Cancer J Clin, 2008, 58(2) : 71-96.
  • 5Shenton KC, Dowsett M, Lu Q, et al. Comparison of biochemical aromatase immunohistochemistry in human breast carcinomas [J]. Breast Cancer Res Treat, 1998,49( suppl 1 ) S101-107 ; 109-119.
  • 6Zhang Z, Yamashita H, Toyama T, et al. Semi-quantitative immunohistochemical analysis of aromatase expression in ductal carcinoma in situ of the breast [ J]. Breast Cancer Res Treat, 2002, 74 ( 1 ) : 47-53.
  • 7Folkman J. Tumor angiogenesis : thrapeutic implication [ J ]. N Engl J Med, 1971, 285(21) : 1182-1186.
  • 8Giatromanolaki A, Sivridis E, Brekken R, et al. The angiogenic “vascular endothelial growth factor/flk-1 (KDR) receptor” pathway in patients with endometrial carcinomal: prognostic and therapeutic implications[J]. Cancer, 2001, 92 (10): 2569-2577.
  • 9Nelson NJ . Angiogenesis research is on fast forward [ J ]. J Natl Cancer Inst, 1999, 91 (10) : 820-822.
  • 10Boehm-Viswanathan T. Is angiogenesis inhibition the Holy Grail of cancer therapy[ J]. Curr Opin Oncol, 2000, 12 (1) : 89-94.

引证文献3

二级引证文献17

中国医药工业杂志
2006年 第2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部